Payment overview · 2025
General Payments
$762.91
33 reported records · 8 companies
Healthcare provider profile · identity verified
Rameen Miarrostami, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1497734743
Verified facts
What the public records show
CMS Open Payments records show Rameen Miarrostami, MD received $762.91 in general payments during 2025 across 33 reported records.
GlaxoSmithKline, LLC. accounted for 58.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $443.55 | 58.1% | 18 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $78.66 | 10.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $77.22 | 10.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.34 | 7.9% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $33.65 | 4.4% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $25.69 | 3.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $24.86 | 3.3% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $18.94 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $762.91 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $406.23 | 16 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $78.66 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $77.22 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $33.65 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 283 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
283 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 659 | 159 |
| Losartan Potassium | Losartan Potassium | 558 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 430 | 162 |
| Metformin Hcl | Metformin Hcl | 417 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 64 |
| Montelukast Sodium | Montelukast Sodium | 291 | 74 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 283 | 72 |
| Omeprazole | Omeprazole | 254 | 69 |
| Simvastatin | Simvastatin | 235 | 65 |
| Gabapentin | Gabapentin | 209 | 62 |
| Lisinopril | Lisinopril | 195 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 39 |
| Breo Ellipta | Fluticasone/Vilanterol | 128 | 25 |
| Famotidine | Famotidine | 127 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 113 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 111 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 27 |
| Ezetimibe | Ezetimibe | 106 | 28 |
| Glimepiride | Glimepiride | 106 | 19 |
| Azithromycin | Azithromycin | 103 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 30 |
| Symbicort | Budesonide/Formoterol Fumarate | 96 | 28 |
| Eliquis | Apixaban | 95 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 84 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 19 |
| Furosemide | Furosemide | 82 | 21 |
| Allopurinol | Allopurinol | 75 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 71 | 15 |
| Methylprednisolone | Methylprednisolone | 67 | 55 |
| Potassium Chloride | Potassium Chloride | 67 | 16 |
| Mirtazapine | Mirtazapine | 64 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 61 | 18 |
| Meloxicam | Meloxicam | 61 | 25 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 59 | 17 |
| Finasteride | Finasteride | 59 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 57 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 12 |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Lorazepam | Lorazepam | 51 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 11 |
| Atenolol | Atenolol | 46 | 13 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Irbesartan | Irbesartan | 46 | suppressed |
| Prednisone | Prednisone | 45 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | 20 |
| Valsartan | Valsartan | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 19 |
| Ibuprofen | Ibuprofen | 35 | 19 |
| Torsemide | Torsemide | 35 | suppressed |
| Ofev | Nintedanib Esylate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 22 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | 11 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $762.91 · 33 records | GlaxoSmithKline, LLC. | ACTHAR, Arikayce, ELIQUIS, NUCALA, NURTEC ODT, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, SMARTVEST, TRELEGY ELLIPTA, Vest Therapy Und, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error